Gland Pharma
- Advice
- Hold
Gland Pharma Performance
Day Range
- Low 1,756.55
- High 1,797.85
52 Week Range
- Low 861.00
- High 1,841.80
- Open Price1,779.95
- Previous Close1,777.75
- Volume65939
Start SIP in Gland Pharma
Start SIPGland Pharma Investment Rating
-
Master Rating:
-
Gland Pharma has an operating revenue of Rs. 4,305.42 Cr. on a trailing 12-month basis. An annual revenue de-growth of -16% needs improvement, Pre-tax margin of 29% is great, ROE of 9% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 28% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -1% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 50 which is a POOR score indicating inconsistency in earnings, a RS Rating of 64 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 1,011 | 884 | 785 | 926 | 1,048 | 857 | 1,103 |
Operating Expenses Qtr Cr | 664 | 625 | 616 | 642 | 753 | 587 | 755 |
Operating Profit Qtr Cr | 347 | 259 | 169 | 284 | 295 | 270 | 348 |
Depreciation Qtr Cr | 40 | 39 | 38 | 38 | 37 | 35 | 31 |
Interest Qtr Cr | 1 | 2 | 2 | 3 | 2 | 1 | 2 |
Tax Qtr Cr | 90 | 66 | 33 | 78 | 83 | 79 | 95 |
Net Profit Qtr Cr | 258 | 188 | 79 | 228 | 240 | 229 | 286 |
Gland Pharma Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹1,726.48
- 50 Day
- ₹1,658.37
- 100 Day
- ₹1,576.03
- 200 Day
- ₹1,566.12
- 20 Day
- ₹1,715.10
- 50 Day
- ₹1,645.09
- 100 Day
- ₹1,583.23
- 200 Day
- ₹1,380.76
Gland Pharma Resistance and Support
Resistance | |
---|---|
First Resistance | 1,796.73 |
Second Resistance | 1,815.72 |
Third Resistance | 1,838.03 |
RSI | 63.63 |
MFI | 77.52 |
MACD Single Line | 45.59 |
MACD | 48.55 |
Support | |
---|---|
First Resistance | 1,755.43 |
Second Resistance | 1,733.12 |
Third Resistance | 1,714.13 |
Gland Pharma Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 321,020 | 22,503,502 | 70.1 |
Week | 322,281 | 21,567,045 | 66.92 |
1 Month | 443,914 | 23,633,959 | 53.24 |
6 Month | 771,106 | 28,014,265 | 36.33 |
Gland Pharma Result Highlights
Gland Pharma Synopsis
NSE-Medical-Generic Drugs
Gland Pharma is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 3616.53 Cr. and Equity Capital is Rs. 16.47 Cr. for the Year ended 31/03/2023. Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276.Market Cap | 29,280 |
Sales | 3,606 |
Shares in Float | 6.92 |
No of funds | 136 |
Yield |
Book Value | 3.68 |
U/D Vol ratio | 1.6 |
LTDebt / Equity | |
Alpha | 0.06 |
Beta | 0.27 |
Gland Pharma
Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|---|
Promoters | 57.86% | 57.86% | 57.86% | 57.86% |
Mutual Funds | 19.79% | 20.48% | 20.25% | 19.49% |
Insurance Companies | 1.79% | 1.8% | 2.02% | 2.59% |
Foreign Portfolio Investors | 4.91% | 2.8% | 4.33% | 4.67% |
Financial Institutions/ Banks | 0.01% | |||
Individual Investors | 4.52% | 5.61% | 4.27% | 4.02% |
Others | 11.12% | 11.45% | 11.27% | 11.37% |
Gland Pharma Management
Name | Designation |
---|---|
Mr. Yiu Kwan Stanley Lau | Chairman & Ind.Director |
Mr. Srinivas Sadu | Managing Director & CEO |
Mr. Qiyu Chen | Non Executive Director |
Mr. Yao Fang | Non Executive Director |
Dr. Jia Ai (Allen) Zhang | Non Executive Director |
Mr. Udo Johannes Vetter | Independent Director |
Mr. Satyanarayana Murthy Chavali | Independent Director |
Mr. Essaji Goolam Vahanvati | Independent Director |
Gland Pharma Forecast
Price Estimates
Gland Pharma Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-11-06 | Quarterly Results | |
2023-08-07 | Quarterly Results | |
2023-05-18 | Audited Results & A.G.M. | |
2023-01-23 | Quarterly Results | |
2022-10-26 | Quarterly Results |
About Gland Pharma
Gland Pharma FAQs
What is Share Price of Gland Pharma ?
Gland Pharma share price is ₹1,792 As on 11 December, 2023 | 12:08
What is the Market Cap of Gland Pharma ?
The Market Cap of Gland Pharma is ₹29529.4 Cr As on 11 December, 2023 | 12:08
What is the P/E ratio of Gland Pharma ?
The P/E ratio of Gland Pharma is 42.3 As on 11 December, 2023 | 12:08
What is the PB ratio of Gland Pharma ?
The PB ratio of Gland Pharma is 3.7 As on 11 December, 2023 | 12:08
Is it a good time to invest in Gland Pharma Limited?
Gland Pharma has an operating revenue of Rs.3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great. Various broking houses and analysts recommend 'BUY' on the stock.
What is the stock price CAGR of Gland Pharma Limited?
The stock price CAGR of Gland Pharma Limited for 1 Year is 66%.
Is Gland Pharma Limited debt-free?
Gland Pharma Limited is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.
What is the ROE of Gland Pharma Limited?
The ROE of Gland Pharma Limited is 16% is which good.
Who is the Managing Director of Gland Pharma Limited?
Mr. Srinivas Sadu is the Managing Director & Chief Executive Officer of Gland Pharma Limited.
How to buy shares of Gland Pharma Ltd online?
The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.
What are some of the competitors of Gland Pharma Ltd?
Given below is the list of companies that belong to the same industry or manufacture products of a similar niche as Gland Pharma Ltd.
- Cipla
- Sun Pharma
- Pfizer
- Lupin
- Eris Life
- Aarti Drugs
- Hester Bio
- RPG Life
- Bafna Pharma
- Jb Chemicals